222 related articles for article (PubMed ID: 12616957)
41. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
42. Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.
Vilhelmsson-Timmermand O; Santos E; Thorek DL; Evans-Axelsson S; Bjartell A; Lilja H; Larson SM; Strand SE; Tran TA; Ulmert D
Nucl Med Biol; 2015 Apr; 42(4):375-80. PubMed ID: 25577038
[TBL] [Abstract][Full Text] [Related]
43. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
Sabbah EN; Kadouche J; Ellison D; Finucane C; Decaudin D; Mather SJ
Nucl Med Biol; 2007 Apr; 34(3):293-304. PubMed ID: 17383579
[TBL] [Abstract][Full Text] [Related]
45.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
46. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Foulon CF; Bigner DD; Zalutsky MR
Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
[TBL] [Abstract][Full Text] [Related]
47. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
[TBL] [Abstract][Full Text] [Related]
48. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
Tolmachev V; Orlova A; Wei Q; Bruskin A; Carlsson J; Gedda L
Cancer Biother Radiopharm; 2004 Aug; 19(4):491-501. PubMed ID: 15453964
[TBL] [Abstract][Full Text] [Related]
49. Radioimmunoimaging with mixed monoclonal antibodies of nude mice bearing human lung adenocarcinoma xenografts.
Duan D; Li SL; Zhu YQ; Zhang T; Lei CM; Cheng XH
Asian Pac J Cancer Prev; 2012; 13(9):4255-61. PubMed ID: 23167324
[TBL] [Abstract][Full Text] [Related]
50. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
Nayak TK; Garmestani K; Milenic DE; Baidoo KE; Brechbiel MW
PLoS One; 2011 Mar; 6(3):e18198. PubMed ID: 21464917
[TBL] [Abstract][Full Text] [Related]
51. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification.
Fernandez-Sánchez E; Ducongé J; Castillo R; Garcia I; Beausoleil I; Macías A
J Pharm Pharmacol; 2002 Jan; 54(1):59-64. PubMed ID: 11829130
[TBL] [Abstract][Full Text] [Related]
52. Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation.
Ingargiola M; Dittfeld C; Runge R; Zenker M; Heldt JM; Steinbach J; Cordes N; Baumann M; Kotzerke J; Kunz-Schughart LA
Cytometry A; 2012 Oct; 81(10):865-73. PubMed ID: 22930585
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and preclinical investigation of
Shah SQ; Gul-E-Raana
Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
[TBL] [Abstract][Full Text] [Related]
55. Antibody labeling with radioiodine and radiometals.
Gupta S; Batra S; Jain M
Methods Mol Biol; 2014; 1141():147-57. PubMed ID: 24567137
[TBL] [Abstract][Full Text] [Related]
56. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
57. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.
Awwad M; Strome PG; Gilman SC; Axelrod HR
Cancer Immunol Immunother; 1994 Jan; 38(1):23-30. PubMed ID: 8299115
[TBL] [Abstract][Full Text] [Related]
58. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical and pharmacokinetic characterization of site-specific immunoconjugate 15A8-glycyl-tyrosyl-(N-epsilon-diethylenetriamine pentaacetic acid)-lysine derived from anti-breast carcinoma monoclonal antibody 15A8.
Rosenstraus MJ; Davis WL; Lopes AD; D'Aleo CJ; Gilman SC
Cancer Res; 1991 Oct; 51(20):5744-51. PubMed ID: 1913693
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]